Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.48 |
| ▸ | SRC | P12931 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | CDK4 | P11802 | 3/20 | 0.46 |
| ▸ | CDK7 | P50613 | 3/20 | 0.46 |
| ▸ | CDK9 | P50750 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.46 |
| ▸ | STK16 | O75716 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.46 |
| ▸ | TYK2 | P29597 | 2/20 | 0.46 |
| ▸ | BMPR2 | Q13873 | 2/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.46 |
| ▸ | NUAK2 | Q9H093 | 2/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.46 |
| ▸ | BMP2K | Q9NSY1 | 2/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065749 | 0.99 | BRD4 (0.48) | BRD4SRCKDRCDK4CDK7 | |
| SCHEMBL4061800 | 0.92 | BRD4 (0.54) | BRD4SRCKDRCDK4CDK7 | |
| SCHEMBL4063259 | 0.91 | KDR (0.54) | BRD4SRCKDRCDK4CDK7 | |
| SCHEMBL4066354 | 0.91 | CDK1 (0.51) | SRCKDRCDK4CDK7CDK9 | |
| SCHEMBL4063419 | 0.90 | KDR (0.55) | BRD4SRCKDRCDK4CDK7 | |
| SCHEMBL4064803 | 0.90 | CDK1 (0.52) | SRCKDRCDK4CDK7CDK9 | |
| SCHEMBL4066724 | 0.87 | BRD4 (0.44) | BRD4SRCKDRCDK4CDK7 | |
| SCHEMBL4064797 | 0.86 | BRD4 (0.44) | BRD4SRCKDRCDK4CDK7 | |
| SCHEMBL4061017 | 0.86 | BRD4 (0.45) | BRD4KDRCDK4CDK7CDK9 | |
| SCHEMBL4061570 | 0.86 | POLB (0.45) | BRD4KDRCDK4CDK7CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392662-B1 | CDK INHIBITING PYRIMIDINES, PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BAYER SCHERING PHARMA AG (DE) | 2009-01-07 | — | — | EP | claimed |
| US-7598260-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-06 | — | — | US | disclosed |
| US-7598260-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-06 | — | — | US | disclosed |
| EP-1392662-B1 | CDK INHIBITING PYRIMIDINES, PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BAYER SCHERING PHARMA AG (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | BRUMBY THOMAS | 2008-02-14 | — | — | US | disclosed |
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | BRUMBY THOMAS | 2008-02-14 | — | — | US | disclosed |
| US-7291624-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7291624-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7235561-B2 | Compound and a composition including such a compound | SCHERING AG (DE) | 2007-06-26 | — | — | US | disclosed |
| US-7235561-B2 | Compound and a composition including such a compound | SCHERING AG (DE) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK1, CDK6 | BRD4 632/4885SRC 1690/4885KDR 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.